Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07479797 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
A Phase 3 study, sponsored by Kite, A Gilead Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 550
- Enrollment target
NCT07479797 is a Phase 3 study that is actively recruiting participants, run by Kite, A Gilead Company. The registered enrollment target is 550 participants.
The verdict
NCT07479797, a Phase 3 study, is actively recruiting participants, sponsored by Kite, A Gilead Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 550 participants
- Enrollment target
Study Summary
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Axicabtagene Ciloleucel
- DRUG KITE-753
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2026-05-22 |
| Est. Completion | 2031-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07479797
The ClinicalTrials.gov registry entry for NCT07479797 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT07479797 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07479797 about?
NCT07479797 is a clinical study titled "Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy". The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KIT...
What is the current status of trial NCT07479797?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 550 participants. The study started on 2026-05-22. Estimated completion is 2031-05.
What interventions are being tested in trial NCT07479797?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Axicabtagene Ciloleucel (DRUG), KITE-753 (DRUG).
Who is sponsoring clinical trial NCT07479797?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.